HRP20100147T1 - Inhibitori proteina akt (protein kinaza b) - Google Patents
Inhibitori proteina akt (protein kinaza b) Download PDFInfo
- Publication number
- HRP20100147T1 HRP20100147T1 HR20100147T HRP20100147T HRP20100147T1 HR P20100147 T1 HRP20100147 T1 HR P20100147T1 HR 20100147 T HR20100147 T HR 20100147T HR P20100147 T HRP20100147 T HR P20100147T HR P20100147 T1 HRP20100147 T1 HR P20100147T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- compound
- treatment
- glioblastoma
- pharmaceutical preparation
- Prior art date
Links
- 108091008611 Protein Kinase B Proteins 0.000 title 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 4
- RECFXYRAGCPZOS-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol Chemical compound C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 RECFXYRAGCPZOS-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000001672 ovary Anatomy 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- WRBAEXPHVMKWSP-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol;hydrochloride Chemical group Cl.C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 WRBAEXPHVMKWSP-UHFFFAOYSA-N 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010029096 Neoplasm prostate Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 201000005404 rubella Diseases 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- LWEAAWDKHBZPDJ-UHFFFAOYSA-N 4-[5-(2-aminoethylsulfonyl)isoquinolin-7-yl]phenol;dihydrochloride Chemical group Cl.Cl.C=1C2=CN=CC=C2C(S(=O)(=O)CCN)=CC=1C1=CC=C(O)C=C1 LWEAAWDKHBZPDJ-UHFFFAOYSA-N 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Spoj, naznačen time što je to 4-[5-(2-amino-etansulfonil)-izokinolin-7-il]-fenol ili njegova farmaceutska prihvatljiva sol, ili hidrat spoja ili njegova sol. Patent sadrži još 19 patentnih zahtjeva.
Claims (20)
1. Spoj, naznačen time što je to 4-[5-(2-amino-etansulfonil)-izokinolin-7-il]-fenol ili njegova farmaceutska prihvatljiva sol, ili hidrat spoja ili njegova sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je to 4-[5-(2-amino-etansulfonil)-izokinolin-7-il]-fenol di-hidroklorid.
3. Spoj prema patentnom zahtjevu 1, naznačen time što je to 4-[5-(2-amino-etansulfonil)-izokinolin-7-il]-fenol monohidroklorid hemihidrat.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi kao lijek.
5. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spoj koristi za proizvodnju lijeka namijenjenog liječenju multiplog mijeloma, nemikrocelularnog raka, glioblastoma, neuroblastoma, melanoma ili neoplazmi prostate, dojke, jajnika, primarno želuca, crijevnog tipa, sluznice, štitnjače, gušterače, pluća ili mjehura.
6. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spoj koristi za proizvodnju lijeka namijenjenog liječenju multiplog mijeloma, nemikrocelularnog raka, glioblastoma ili neoplazmi prostate, dojke ili jajnika.
7. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spoj koristi za proizvodnju lijeka namijenjenog liječenju nemikrocelularnog raka ili glioblastoma.
8. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spoj koristi za proizvodnju lijeka namijenjenog liječenju hepatitisa C, rubele, virusa humane imunodeficijencije (HIV), hepatitisa B ili humanog citomegalovirusa (HCMV).
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi u liječenju multiplog mijeloma, nemikrocelularnog raka, glioblastoma, neuroblastoma, melanoma ili neoplazmi prostate, dojke, jajnika, primarno želuca, crijevnog tipa, sluznice, štitnjače, gušterače, pluća ili mjehura.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi u liječenju multiplog mijeloma, nemikrocelularnog raka, glioblastoma ili neoplazmi prostate, dojke ili jajnika.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi u liječenju nemikrocelularnog raka ili glioblastoma.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi u liječenju hepatitisa C, rubele, virusa humane imunodeficijencije (HIV), hepatitisa B ili humanog citomegalovirusa (HCMV).
13. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipient.
14. Liofilizirani farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipient pri čemu pH spomenutog pripravka kada je razrijeđen s vodenastim razrjeđivačem je manji od 4,2 i veći od 2,0.
15. Liofilizirani farmaceutski pripravak prema patentnom zahtjevu 14, naznačen time što pH je manji od 3,2 i veći od 2,0.
16. Liofilizirani farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time što pH je manji od 2,8 i veći od 2,0.
17. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipient u otopini pri čemu pH spomenutog pripravka je manji od 4,2 i veći od 2,0.
18. Farmaceutski pripravak prema patentnom zahtjevu 17, naznačen time što pH spomenutog pripravka je manji od 3,2 i veći od 2,0.
19. Farmaceutski pripravak prema patentnom zahtjevu 18, naznačen time što pH spomenutog pripravka je manji od 2,8 i veći od 2,0.
20. 4-[5-(2-amino-etansulfonil)-izokinolin-7-il]-fenol monohidroklorid hemihidrat u kristalnom obliku, naznačen time što ima difrakcijski uzorak X-zraka na prahu s istaknutim vršnim vrijednostima pri 2θ = 4,9, 14,8, i 10,2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80526006P | 2006-06-20 | 2006-06-20 | |
| US88576507P | 2007-01-19 | 2007-01-19 | |
| PCT/US2007/070945 WO2007149730A2 (en) | 2006-06-20 | 2007-06-12 | Inhibitors of akt (protein kinase b) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100147T1 true HRP20100147T1 (hr) | 2010-04-30 |
Family
ID=38834248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100147T HRP20100147T1 (hr) | 2006-06-20 | 2010-03-15 | Inhibitori proteina akt (protein kinaza b) |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7998977B2 (hr) |
| EP (1) | EP2035385B1 (hr) |
| JP (1) | JP2009541335A (hr) |
| KR (1) | KR101067551B1 (hr) |
| AR (1) | AR061240A1 (hr) |
| AT (1) | ATE455102T1 (hr) |
| AU (1) | AU2007261120A1 (hr) |
| BR (1) | BRPI0713136A2 (hr) |
| CA (1) | CA2652612A1 (hr) |
| CL (1) | CL2007001752A1 (hr) |
| DE (1) | DE602007004333D1 (hr) |
| DK (1) | DK2035385T3 (hr) |
| DO (1) | DOP2008000053A (hr) |
| EA (1) | EA015712B1 (hr) |
| EC (1) | ECSP088992A (hr) |
| ES (1) | ES2336630T3 (hr) |
| HR (1) | HRP20100147T1 (hr) |
| IL (1) | IL195005A0 (hr) |
| MA (1) | MA30757B1 (hr) |
| MX (1) | MX2008015904A (hr) |
| NO (1) | NO20090289L (hr) |
| PE (1) | PE20080338A1 (hr) |
| PL (1) | PL2035385T3 (hr) |
| PT (1) | PT2035385E (hr) |
| SI (1) | SI2035385T1 (hr) |
| TN (1) | TNSN08529A1 (hr) |
| TW (1) | TW200812970A (hr) |
| WO (1) | WO2007149730A2 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146320A1 (en) | 2008-05-27 | 2009-12-03 | Dmi Life Sciences, Inc. | Therapeutic methods and compounds |
| JP2013537195A (ja) | 2010-09-07 | 2013-09-30 | ディエムアイ アクイジション コーポレイション | 疾患の治療 |
| AU2012323305B2 (en) | 2011-10-10 | 2017-07-27 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
| MY172699A (en) | 2011-10-10 | 2019-12-10 | Ampio Pharmaceuticals Inc | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
| EP2771007B1 (en) | 2011-10-28 | 2018-04-04 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| EA201500943A1 (ru) | 2013-03-15 | 2016-08-31 | Ампио Фармасьютикалс, Инк. | Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| KR20170045274A (ko) | 2014-08-18 | 2017-04-26 | 앰피오 파마슈티컬스 인코퍼레이티드 | 관절 징후의 치료 |
| WO2016201605A1 (zh) * | 2015-06-15 | 2016-12-22 | 廖勇 | 一种治疗乙型肝炎病毒的靶点 |
| WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CA3186565A1 (en) * | 2020-07-22 | 2022-01-27 | Lei Miao | Unit dosage composition of akt inhibitor |
| US20230271958A1 (en) * | 2020-07-22 | 2023-08-31 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152807A0 (en) | 2000-05-30 | 2003-06-24 | Peptor Ltd | Protein kinase inhibitors |
| CN1768040A (zh) | 2003-03-28 | 2006-05-03 | 伊莱利利公司 | 作为akt(蛋白激酶b)抑制剂的异喹啉－5－磺酸酰胺 |
| GB0317315D0 (en) | 2003-07-24 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
-
2007
- 2007-06-06 AR ARP070102429A patent/AR061240A1/es unknown
- 2007-06-12 CA CA002652612A patent/CA2652612A1/en not_active Abandoned
- 2007-06-12 MX MX2008015904A patent/MX2008015904A/es active IP Right Grant
- 2007-06-12 AT AT07798410T patent/ATE455102T1/de active
- 2007-06-12 SI SI200730212T patent/SI2035385T1/sl unknown
- 2007-06-12 DK DK07798410.2T patent/DK2035385T3/da active
- 2007-06-12 JP JP2009516633A patent/JP2009541335A/ja not_active Ceased
- 2007-06-12 PT PT07798410T patent/PT2035385E/pt unknown
- 2007-06-12 ES ES07798410T patent/ES2336630T3/es active Active
- 2007-06-12 DE DE602007004333T patent/DE602007004333D1/de active Active
- 2007-06-12 EA EA200970041A patent/EA015712B1/ru not_active IP Right Cessation
- 2007-06-12 US US12/300,358 patent/US7998977B2/en not_active Expired - Fee Related
- 2007-06-12 KR KR1020087030916A patent/KR101067551B1/ko not_active IP Right Cessation
- 2007-06-12 BR BRPI0713136-4A patent/BRPI0713136A2/pt not_active IP Right Cessation
- 2007-06-12 EP EP07798410A patent/EP2035385B1/en active Active
- 2007-06-12 PL PL07798410T patent/PL2035385T3/pl unknown
- 2007-06-12 AU AU2007261120A patent/AU2007261120A1/en not_active Abandoned
- 2007-06-12 WO PCT/US2007/070945 patent/WO2007149730A2/en active Application Filing
- 2007-06-15 CL CL2007001752A patent/CL2007001752A1/es unknown
- 2007-06-18 PE PE2007000768A patent/PE20080338A1/es not_active Application Discontinuation
- 2007-06-20 TW TW096122142A patent/TW200812970A/zh unknown
-
2008
- 2008-10-24 DO DO2008000053A patent/DOP2008000053A/es unknown
- 2008-10-30 IL IL195005A patent/IL195005A0/en unknown
- 2008-12-18 EC EC2008008992A patent/ECSP088992A/es unknown
- 2008-12-19 TN TNP2008000529A patent/TNSN08529A1/en unknown
-
2009
- 2009-01-19 NO NO20090289A patent/NO20090289L/no not_active Application Discontinuation
- 2009-01-19 MA MA31573A patent/MA30757B1/fr unknown
-
2010
- 2010-03-15 HR HR20100147T patent/HRP20100147T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080338A1 (es) | 2008-04-25 |
| WO2007149730A3 (en) | 2008-04-24 |
| DE602007004333D1 (de) | 2010-03-04 |
| KR101067551B1 (ko) | 2011-09-27 |
| MA30757B1 (fr) | 2009-10-01 |
| MX2008015904A (es) | 2009-01-12 |
| NO20090289L (no) | 2009-01-19 |
| TW200812970A (en) | 2008-03-16 |
| US20090221633A1 (en) | 2009-09-03 |
| DOP2008000053A (es) | 2009-01-15 |
| TNSN08529A1 (en) | 2010-04-14 |
| KR20090015978A (ko) | 2009-02-12 |
| EA015712B1 (ru) | 2011-10-31 |
| ECSP088992A (es) | 2009-01-30 |
| ES2336630T3 (es) | 2010-04-14 |
| BRPI0713136A2 (pt) | 2012-04-17 |
| CA2652612A1 (en) | 2007-12-27 |
| CL2007001752A1 (es) | 2008-01-18 |
| PT2035385E (pt) | 2010-03-01 |
| AU2007261120A1 (en) | 2007-12-27 |
| EA200970041A1 (ru) | 2009-06-30 |
| JP2009541335A (ja) | 2009-11-26 |
| AR061240A1 (es) | 2008-08-13 |
| WO2007149730A2 (en) | 2007-12-27 |
| ATE455102T1 (de) | 2010-01-15 |
| IL195005A0 (en) | 2009-08-03 |
| SI2035385T1 (sl) | 2010-05-31 |
| EP2035385B1 (en) | 2010-01-13 |
| PL2035385T3 (pl) | 2010-06-30 |
| US7998977B2 (en) | 2011-08-16 |
| DK2035385T3 (da) | 2010-03-22 |
| EP2035385A2 (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100147T1 (hr) | Inhibitori proteina akt (protein kinaza b) | |
| EA038122B9 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20191979T1 (hr) | Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima | |
| CN104334563B (zh) | 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途 | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| WO2007042786A3 (en) | 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| UA90763C2 (ru) | Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| SG11201901894TA (en) | Anti-influenza virus pyrimidine derivatives | |
| MX359200B (es) | Inhibidores de cinasa. | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX2018009741A (es) | Composicion farmaceutica que contiene un inhibidor de janus quinasa o una sal farmaceuticamente aceptable del mismo. | |
| EA200800502A1 (ru) | Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения | |
| AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer | |
| MX2019013815A (es) | Inhibidor de antigenos de superficie del virus de la hepatitis b. | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| HRP20100678T1 (hr) | Derivati heteroariluree korisni kao inhibitori chk1 | |
| MY167216A (en) | Kinase inhibitors | |
| EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| HRP20110244T1 (hr) | Postupak liječenja raka | |
| MX2016001896A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico. |